Showing results (161-170 of 179) with videos related to
Sort By:
Pageof 18
Journal for Immunotherapy of Cancer|March 13, 2026
Phase Ib multicenter study of anti-TIM-3 (S095018/Sym023) in combination with anti-PD-1 (Sym021) in patients with advanced/metastatic recurrent biliary tract cancerFrancois Ghiringhelli, Richard Kim, Teresa Macarulla, et al.JCO Precision Oncology|July 2, 2025
Feasibility of Personalized and Tumor-Informed Circulating Tumor DNA Assay for Early Recurrence Detection in Patients With Hepatocellular CarcinomaMaen Abdelrahim, Alejandro Mejia, Abdullah Esmail, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2024
SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract CancersRachna T Shroff, Gentry King, Sarah Colby, et al.Frontiers in Oncology|May 28, 2021
Predicting Adverse Pathologic Features and Clinical Outcomes of Resectable Pancreas Cancer With Preoperative CA 19-9Roman O Kowalchuk, Scott C Lester, Rondell P Graham, et al.Journal for Immunotherapy of Cancer|February 6, 2025
Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer typesDavid R Gandara, Neeraj Agarwal, Shilpa Gupta, et al.JCO Precision Oncology|February 1, 2022
Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR AlterationsDavid M Hyman, Ben Tran, Luis Paz-Ares, et al.JAMA Network Open|September 12, 2025
Circulating Tumor DNA and Tissue Testing for Pancreatobiliary TumorsHimil Mahadevia, Umair Majeed, Jaydeepbhai Patel, et al.Journal of Gastrointestinal Oncology|November 18, 2021
Intact SMAD-4 is a predictor of increased locoregional recurrence in upfront resected pancreas cancer receiving adjuvant therapyHunter C Gits, Amy H Tang, William S Harmsen, et al.Future Oncology (London, England)|June 17, 2024
Plain language summary of the FOENIX-CCA2 study: futibatinib for people with advanced bile duct cancerLipika Goyal, Funda Meric-Bernstam, Antoine Hollebecque, et al.Journal of Hepatology|August 14, 2025
Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinomaTim Meyer, Richard S Finn, Mitesh Borad, et al.Pageof 18